TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, announced that its board of directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its oncology portfolio, including lead product candidate TTX-MC138. The review will consider potential licensing or sales of individual assets, development and commercialization partnerships, portfolio transactions, business combinations and other strategic alternatives. TransCode has engaged Tungsten Advisors as its exclusive strategic financial adviser for the process.
TTX-MC138, an investigational RNA-based therapeutic targeting microRNA-10b, has advanced into Phase 2a clinical development following a Phase 1a study that provided initial safety data and reports of stable disease. The ongoing trial is evaluating the treatment in patients with circulating tumor DNA-positive colorectal cancer following curative-intent therapy, in collaboration with Quantum Leap Healthcare Collaborative. TransCode also recently announced a collaboration with Natera Inc. to use its Signatera test to identify eligible patients and support trial enrollment.
Chairman and CEO Philippe P. Calais said the strategic review is intended to identify opportunities to advance the company’s oncology programs while seeking to maximize stockholder value. TransCode cautioned that the process may not result in a transaction or other strategic outcome. The announcement signals a potential shift in strategy for the clinical-stage company, which has been focused on developing its pipeline of RNA therapeutics and immuno-oncology treatments. For investors, the review could lead to a range of outcomes, from licensing deals to an outright sale, but the company’s caution underscores the uncertainty inherent in such processes.
The news comes as TransCode continues to advance TTX-MC138 in the clinic. The Phase 2a trial is evaluating the candidate in patients with circulating tumor DNA-positive colorectal cancer after curative-intent therapy, a setting where there is a significant unmet need for therapies that can prevent recurrence. The collaboration with Natera and Quantum Leap Healthcare Collaborative aims to streamline patient identification and enrollment, potentially accelerating the trial’s progress.
TransCode’s portfolio also includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The strategic review will assess the value of these assets alongside TTX-MC138, with the goal of maximizing value for stockholders. The company’s decision to engage Tungsten Advisors as exclusive financial adviser suggests a thorough evaluation of options. The full press release can be viewed at https://ibn.fm/AGxas, and the latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.
The announcement was distributed by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences and life sciences sectors. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. The company’s website is https://www.BioMedWire.com, and full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
